ACHIEVE LIFE SCIENCES, INC.
ACHV · XNASCIK 949858fmd_01SPE47R2V4BQSZDFWRHHHGTE9Manufacturing · In Vitro & In Vivo Diagnostic SubstancesTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2026, 67 periods
Latest annual · FY2025
Millions- Net income
- (55)
- Free cash flow
- (49)
Latest quarter · Q3 FY2026
Millions- Net income
- (12)
- Free cash flow
- (8)
Daily close · ACHVIEX trades only
Nov 11, 2025 to Nov 09, 2026 · 250 sessions6.80 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Key stats
Open AnalysisCompound annual growth
- Net income, 5 yearsFY2020 to FY2025
- n/m
ACHIEVE LIFE SCIENCES, INC. (ACHV) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Net income | -$54.6 million | -$39.8 million | 10-K 2026-03-24 · proof | |
| Cash from operating activities | -$49.5 million | -$29.8 million | 10-K 2026-03-24 · proof | |
| Free cash flow | -$49.5 million | 10-K 2026-03-24 · proof | ||
| Total assets | $41.8 million | $38.6 million | +8.2% | 10-K 2026-03-24 · proof |
| Total liabilities | $20.3 million | $17.7 million | +14.3% | 10-K 2026-03-24 · proof |
| Cash and cash equivalents | $20.9 million | $12.8 million | +64.1% | 10-K 2026-03-24 · proof |
- What was ACHIEVE LIFE SCIENCES, INC. (ACHV)'s net income in fiscal 2025?
- ACHIEVE LIFE SCIENCES, INC. (ACHV) reported net income of -$54.6 million for fiscal 2025 (the year ended Dec 31, 2025), against -$39.8 million the year before. Source: the 10-K filed with the SEC on Mar 24, 2026. SEC
- What was ACHIEVE LIFE SCIENCES, INC. (ACHV)'s cash from operating activities in fiscal 2025?
- ACHIEVE LIFE SCIENCES, INC. (ACHV) reported cash from operating activities of -$49.5 million for fiscal 2025 (the year ended Dec 31, 2025), against -$29.8 million the year before. Source: the 10-K filed with the SEC on Mar 24, 2026. SEC
- What was ACHIEVE LIFE SCIENCES, INC. (ACHV)'s free cash flow in fiscal 2025?
- ACHIEVE LIFE SCIENCES, INC. (ACHV) reported free cash flow of -$49.5 million for fiscal 2025 (the year ended Dec 31, 2025). Source: the 10-K filed with the SEC on Mar 24, 2026. SEC
- What are ACHIEVE LIFE SCIENCES, INC. (ACHV)'s total assets?
- As of Dec 31, 2025, ACHIEVE LIFE SCIENCES, INC. (ACHV) reported total assets of $41.8 million, against $38.6 million a year earlier (+8.2%). Source: the 10-K filed with the SEC on Mar 24, 2026. SEC
- What are ACHIEVE LIFE SCIENCES, INC. (ACHV)'s total liabilities?
- As of Dec 31, 2025, ACHIEVE LIFE SCIENCES, INC. (ACHV) reported total liabilities of $20.3 million, against $17.7 million a year earlier (+14.3%). Source: the 10-K filed with the SEC on Mar 24, 2026. SEC
- What are ACHIEVE LIFE SCIENCES, INC. (ACHV)'s cash and cash equivalents?
- As of Dec 31, 2025, ACHIEVE LIFE SCIENCES, INC. (ACHV) reported cash and cash equivalents of $20.9 million, against $12.8 million a year earlier (+64.1%). Source: the 10-K filed with the SEC on Mar 24, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:ACHV&period_type=annual&limit=5"Information only, not investment advice.